newsfilter
← Latest News
GlobeNewswire·

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

  • Dogwood Therapeutics (NASDAQ: DWTX) will host a virtual Key Opinion Leader event on September 1, 2026, at 10:00 AM Eastern Time.
  • The event will feature speakers J. Mark Joyce, Iain Dukes, & Jerry Evarts to discuss chemotherapy-induced neuropathic pain (CINP) & Halneuron's Na V 1.7 mechanism.
  • Management will review Halneuron's pre-clinical & clinical data, including interim results from the ongoing Phase 2b CINP study & the advancement of its synthetic Tetrodotoxin formulation for Phase 3.
  • The HAL-CINP trial (NCT06848348) is a randomized study of ~210 to 240 patients evaluating Halneuron versus placebo over 14 days of dosing with 28 days of follow-up.
  • Halneuron has received Fast Track designation from the FDA & has been tested on over 800 patients to date.
  • Dogwood's pipeline also includes SP16 IV, an LRP1 agonist with a Phase 1b trial fully funded by the National Cancer Institute.
  • The company's largest shareholder is a member of CK Life Sciences Int'l., which trades on the Hong Kong Stock Exchange.